Micafungine Biocon

Micafungin, the active ingredient in Micafungine, is an echinocandin presented as an injectable solution for intravenous use. Approved in the European Union, it treats invasive candidiasis, esophageal candidiasis, candidemia and provides prophylaxis of fungal infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company ensures quality compliance and reliable cold‑chain logistics for global distribution.

Micafungine is indicated for several serious fungal infections affecting the bloodstream and mucosal surfaces.

- Invasive candidiasis: effective treatment of deep‑tissue Candida infections in immunocompromised patients. - Esophageal candidiasis: resolves mucosal Candida lesions and associated dysphagia. - Candidemia: clears bloodstream Candida infections and reduces mortality. - Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal disease during periods of severe neutropenia.

Common side effects are generally mild and related to infusion or transient laboratory changes.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or rigors. - Fever: transient elevation during or after infusion. - Nausea: mild gastrointestinal upset. - Headache: occasional dull or throbbing pain. - Elevated liver enzymes: transient increase in ALT or AST. - Rash: mild erythematous skin eruption.

Serious or Rare Side Effects: - Severe hepatic failure: marked elevation of liver enzymes or jaundice. - Anaphylaxis: acute, life‑threatening hypersensitivity reaction. - Severe hypersensitivity: including angioedema or bronchospasm. - Renal dysfunction: acute kidney injury or worsening renal function. - Severe hypotension: sudden drop in blood pressure during infusion. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

- Renal function: monitor serum creatinine and urine output. - Hepatic function: check baseline liver enzymes and repeat during treatment. - Drug interactions: review concomitant medications for potential CYP interactions. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Infusion monitoring: administer under medical supervision and observe for reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine may interact with several drug classes; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce micafungin exposure and efficacy. - Azole antifungals (e.g., fluconazole): may increase micafungin plasma levels and toxicity. - Rifampin: may markedly decrease micafungin concentrations.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., tacrolimus, cyclosporine): may increase drug levels; monitor troughs. - Statins (e.g., simvastatin): risk of myopathy; consider dose adjustment. - Warfarin: potential alteration of INR; monitor coagulation parameters.